Respuesta :
Due to the molecular complexity of major depressive disorder (MDD), there are currently no objective diagnostic biomarkers for the condition. For the clinical diagnosis of MDD, the availability of blood-based biomarkers with high specificity would be useful.
- A thorough plasma proteome investigation was carried out in a highly homogeneous cohort [7 drug-naive MDD patients and 7 healthy controls (HCs)], and potential proteins were screened using bioinformatics analysis and machine learning.
- In separate cohorts of patients with 60 HCs, 74 MDD, 42 cases of schizophrenia (SZ), and 39 cases of bipolar I disorder (BD-I), repeatability and specificity were verified.
- Additionally, proteomic analysis of postmortem brain tissue from 16 HCs and 16 MDD patients was used to confirm consistency.
What results can be observed?
- Both the discovery cohort and the independent replication cohort found that the levels of C-reactive protein (CRP), antithrombin III (ATIII), inter-alpha-trypsin inhibitor heavy chain 4 (ITIH4), and vitamin D-binding protein (VDB) were considerably greater in MDD patients.
- Only patients with MDD had significantly higher levels of two proteins (VDB and ITIH4) in contrast to SZ or BD-I patients.
- Additionally, MDD patients' plasma and postmortem dorsolateral prefrontal brain tissues consistently showed elevated VDB and ITIH4.
- Additionally, a panel with all four plasma proteins had the highest specificity for separating MDD patients from HCs, SZ, or BD-I patients.
What can be concluded?
- Plasma ITIH4 and VDB may be highly specific possible plasma biomarkers of MDD.
- A more acceptable candidate for a clinical diagnostic marker for MDD is the four-protein panel.
To learn more about biomarkers visit?
https://brainly.com/question/28044567
#SPJ4
